a Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva , Geneva , Switzerland.
Expert Rev Anti Infect Ther. 2019 Aug;17(8):557-569. doi: 10.1080/14787210.2019.1645007. Epub 2019 Jul 25.
: Among the multidrug resistant pathogens, extended-spectrum beta-lactamase (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE) are currently considered the main threat due to the scarcity of therapeutic options and their rapid spread around the globe. In addition to developing new antibiotics and stopping transmission, recent research has focused on 'decolonization' strategies to eradicate the carriage of ESBL-E/CPE before infection occurs. : In this narrative review, we aim to describe the current evidence of decolonization strategies for ESBL-E or CPE intestinal carriage. We first define decolonization and highlight the issues related to the lack of standardized definitions, then we summarize the available data on the natural history of colonization. Finally, we review the strategies assessed over the past 10 years for ESBL and CPE decolonization: oral antibiotics, probiotics and more recently fecal microbiota transplantation. We conclude by presenting the risks and uncertainties associated with these strategies. : The evidence available today is too low to recommend decolonization strategies for ESBL-E or CPE in routine clinical practice. The potential increase of resistance and the impact of microbiome manipulation should not be underestimated. Some of these decolonization strategies may nevertheless be effective, at least in temporarily suppressing colonization, which could be useful for specific populations such as high-risk patients. Effectiveness and long-term effects must be properly assessed through well-designed randomized controlled trials.
在多种耐药病原体中,由于治疗选择有限且在全球范围内迅速传播,扩展谱β-内酰胺酶(ESBL-E)或产碳青霉烯酶肠杆菌科(CPE)目前被认为是主要威胁。除了开发新的抗生素和阻止传播外,最近的研究还集中在“去定植”策略上,即在感染发生之前消除 ESBL-E/CPE 的携带。
在这篇叙述性评论中,我们旨在描述 ESBL-E 或 CPE 肠道定植的去定植策略的现有证据。我们首先定义去定植,并强调缺乏标准化定义相关的问题,然后总结关于定植自然史的现有数据。最后,我们回顾了过去 10 年中评估的用于 ESBL 和 CPE 去定植的策略:口服抗生素、益生菌,以及最近的粪便微生物群移植。最后,我们介绍了与这些策略相关的风险和不确定性。
目前的证据太低,无法在常规临床实践中推荐 ESBL-E 或 CPE 的去定植策略。不应低估潜在的耐药性增加和微生物组操作的影响。这些去定植策略中的一些可能仍然有效,至少可以暂时抑制定植,这对于高危人群等特定人群可能有用。必须通过精心设计的随机对照试验来正确评估有效性和长期效果。